Home > Insider Trading > Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. (REGN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
51 - 60
Next >>

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript (Corrected)

Operator: Welcome to the Regeneron Pharmaceuticals' Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.

Keep Reading →

February 8th, 2023 - News Transcripts

Top 25 Smartest Companies To Buy According To Hedge Funds

Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless endeavor, and shareholder and investor interest reign supreme for each company.

Keep Reading →

February 1st, 2023 - Lists News

15 Most Undervalued Quality Stocks To Buy According To Hedge Funds

In this article, we discuss 15 most undervalued quality stocks to buy according to hedge funds.

Keep Reading →

January 26th, 2023 - Hedge Funds News

12 Cheap Biotech Stocks To Buy

Some of the more famous names in the biotech space include companies like Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV).

Keep Reading →

January 25th, 2023 - Hedge Funds News

15 Best S&P 500 Stocks That Don't Pay Dividends

In this article, we will be taking a look at the 15 best S&P 500 stocks that don't pay dividends.

Keep Reading →

December 13th, 2022 - Hedge Funds News

5 Best Immunology Stocks to Invest In

Xencor, Inc.

Keep Reading →

December 13th, 2022 - Hedge Funds News

5 Stocks That May Be Splitting Soon

AutoZone, Inc. (NYSE:AZO) is a leading retailer and one of the largest distributors of automotive parts and accessories in the United States.

Keep Reading →

November 10th, 2022 - Hedge Funds News

10 Latest Earnings That Surprised Wall Street

In this article, we will take a look at the 10 latest earnings that surprised Wall Street.

Keep Reading →

November 4th, 2022 - News

Is Regeneron Pharmaceuticals (REGN) an Attractive Long-Term Stock?

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here.

Keep Reading →

October 27th, 2022 - Hedge Fund Investor Letters News

Is it a Good Decision to Add Regeneron Pharmaceuticals (REGN) to Your Portfolio?

Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here.

Keep Reading →

October 23rd, 2022 - Hedge Fund Investor Letters News